A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). Overall design: Patients were ra
*p-value from a comparison of the three treatment groups using Fisher's exact test. % refers to the proportion of children who reported an adverse event on any occasion after drug administration.
Most common adverse events overall (regardless of causality) occurring in at least two patients in either treatment group (intention-to-treat/safety population).